Trial Profile
A Randomized Phase III Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 30 Apr 2015
Price :
$35
*
At a glance
- Drugs Eflornithine (Primary) ; Sulindac (Primary)
- Indications Familial adenomatous polyposis
- Focus Therapeutic Use
- Sponsors Cancer Prevention Pharmaceuticals
- 31 May 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 06 Dec 2010 New trial record